Machine learning approaches for drug combination therapies
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Drug combination therapy is a promising strategy to treat complex diseases such as cancer and infectious diseases. However, current knowledge of drug combination therapies, especially in cancer patients, is limited because of adverse drug effects, toxicity and cell line heterogeneity. Screening new drug combinations requires substantial efforts since considering all possible combinations between drugs is infeasible and expensive. Therefore, building computational approaches, particularly machine learning methods, could provide an effective strategy to overcome drug resistance and improve therapeutic efficacy. In this review, we group the state-of-the-art machine learning approaches to analyze personalized drug combination therapies into three categories and discuss each method in each category. We also present a short description of relevant databases used as a benchmark in drug combination therapies and provide a list of well-known, publicly available interactive data analysis portals. We highlight the importance of data integration on the identification of drug combinations. Finally, we address the advantages of combining multiple data sources on drug combination analysis by showing an experimental comparison.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“machine learning methods can efficiently predict the synergistic effects of drug combinations by integrating various data sources, such as gene expression data, drug chemical structures, and protein interaction networks.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [489]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111 · cited 1×
“D R E A M [ 16 ] , M S i g D B = M o l e c u l a r s i g n a t u r e s d a t a b a s e [ 72 ] , O N E I L [ 33 ] , A rr ayE x p r e ss d a t a b a s e [ 73 ] , combination therapies has started to gain attention from researchers.”
BackgroundLamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
BioGRID: a general repository for interaction datasets
Stark, C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj109 · Cited by 3,960
KEGG for representation and analysis of molecular networks involving diseases and drugs
Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp896 · Cited by 2,322
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090
Uncovering disease-disease relationships through the incomplete interactome
Menche, J., Sharma, A., Kitsak, M., Ghiassian, S. D., Vidal, M., Loscalzo, J., & Barabási, A.-L. (2015) · Science · doi:10.1126/science.1257601 · Cited by 1,546
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070 · cited 1×
“The usage of drug combinations has multiple advantages over monotherapy, such as higher efficacy and lower toxicity [9, 10].”
Background
Research works printed but not linked: 59
- Pemovska, 2018, Recent advances in combinatorial drug screening and synergy scoring, Curr Opin Pharmacol, 42, 102, 10.1016/j.coph.2018.07.008 · DOI
- Lopez, 2017, Combine and conquer: challenges for targeted therapy combinations in early phase trials, Nat Rev Clin Oncol, 14, 57, 10.1038/nrclinonc.2016.96 · DOI · Paper page
- Ryall, 2015, Systems biology approaches for advancing the discovery of effective drug combinations, J Chem, 7, 1
- Bulusu, 2016, Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives, Drug Discov Today, 21, 225, 10.1016/j.drudis.2015.09.003 · DOI · Paper page
- Sheng, 2018, Advances in computational approaches in identifying synergistic drug combinations, Brief Bioinform, 19, 1172
- Madani Tonekaboni, 2018, Predictive approaches for drug combination discovery in cancer, Brief Bioinform, 19, 263, 10.1093/bib/bbw104 · DOI · Paper page
- Hasselt, 2019, Systems pharmacology: defining the interactions of drug combinations, Annu Rev Pharmacol Toxicol, 59, 21, 10.1146/annurev-pharmtox-010818-021511 · DOI
- Tsigelny, 2019, Artificial intelligence in drug combination therapy, Brief Bioinform, 20, 1434, 10.1093/bib/bby004 · DOI · Paper page
- Jia, 2009, Mechanisms of drug combinations: interaction and network perspectives, Nat Rev Drug Discov, 8, 111, 10.1038/nrd2683 · DOI · Paper page
- Liu, 2018, Anti-cancer drug response prediction using neighbor-based collaborative filtering with global effect removal, Mol Ther Nucleic Acids, 13, 303, 10.1016/j.omtn.2018.09.011 · DOI
- Güvenç Paltun, 2021, Diverse: Bayesian data integrative learning for precise drug response prediction, IEEE/ACM Trans Comput Biol Bioinform, 1, 10.1109/TCBB.2021.3065535 · DOI
- Tang, 2013, Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways, PLoS Comput Biol, 9, 10.1371/journal.pcbi.1003226 · DOI · Paper page
- Tang, 2014, Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles, Curr Pharm Des, 20, 23, 10.2174/13816128113199990470 · DOI · Paper page
- Jaeger, 2017, Quantification of pathway cross-talk reveals novel synergistic drug combinations for breast cancer, Cancer Res, 77, 459, 10.1158/0008-5472.CAN-16-0097 · DOI · Paper page
- Saputra, 2018, Combination therapy and the evolution of resistance: the theoretical merits of synergism and antagonism in cancer, Cancer Res, 78, 2419, 10.1158/0008-5472.CAN-17-1201 · DOI
- Ianevski, 2020, Syntoxprofiler: an interactive analysis of drug combination synergy, toxicity and efficacy, PLoS Comput Biol, 16, 10.1371/journal.pcbi.1007604 · DOI · Paper page
- Tang, 2015, What is synergy? The Saariselkä agreement revisited, Front Pharmacol, 6, 181, 10.3389/fphar.2015.00181 · DOI · Paper page
- Gayvert, 2017, A computational approach for identifying synergistic drug combinations, PLoS Comput Biol, 13, 10.1371/journal.pcbi.1005308 · DOI · Paper page
- Doroshow, 2017, On the design of combination cancer therapy, Cell, 171, 1476, 10.1016/j.cell.2017.11.035 · DOI
- Scott, 2020, Dolutegravir/lamivudine single-tablet regimen: a review in HIV-1 infection, Drugs, 80, 61, 10.1007/s40265-019-01247-1 · DOI
- Spain, 2016, Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations, Expert Opin Pharmacother, 17, 1031, 10.1517/14656566.2016.1168805 · DOI
- Iwata, 2015, Large-scale prediction of beneficial drug combinations using drug efficacy and target profiles, J Chem Inf Model, 55, 2705, 10.1021/acs.jcim.5b00444 · DOI
- Zhao, 2013, Systems pharmacology of adverse event mitigation by drug combinations, Sci Transl Med, 5, 10.1126/scitranslmed.3006548 · DOI · Paper page
- Das, 2018, A survey of the structures of US FDA approved combination drugs, J Med Chem, 62, 4265, 10.1021/acs.jmedchem.8b01610 · DOI · Paper page
- Liu, 2010, DCDB: drug combination database, Bioinformatics, 26, 587, 10.1093/bioinformatics/btp697 · DOI · Paper page
- Hare, 1990, The Orange Book: the Food and Drug Administration’s advice on therapeutic equivalence, Am Pharm, 35–37
- Menden, 2019, Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen, Nat Commun, 10, 1, 10.1038/s41467-019-09799-2 · DOI · Paper page
- Chen, 2014, ASDCD: antifungal synergistic drug combination database, PloS one, 9, 10.1371/journal.pone.0086499 · DOI · Paper page
- Preuer, 2018, DeepSynergy: predicting anti-cancer drug synergy with deep learning, Bioinformatics, 34, 1538, 10.1093/bioinformatics/btx806 · DOI · Paper page
- Guo, 2021, Network controllability-based algorithm to target personalized driver genes for discovering combinatorial drugs of individual patients, Nucleic Acids Res, 49, e37, 10.1093/nar/gkaa1272 · DOI
- Julkunen, 2020, comboFM: leveraging multi-way interactions for systematic prediction of drug combination effects, bioRxiv
- Di Veroli, 2016, Combenefit: an interactive platform for the analysis and visualization of drug combinations, Bioinformatics, 32, 2866, 10.1093/bioinformatics/btw230 · DOI · Paper page
- Ianevski, 2017, SynergyFinder: a web application for analyzing drug combination dose–response matrix data, Bioinformatics, 33, 2413, 10.1093/bioinformatics/btx162 · DOI · Paper page
- Güvenç Paltun, 2021, Improving drug response prediction by integrating multiple data sources: matrix factorization, kernel and network-based approaches, Brief Bioinform, 22, 346, 10.1093/bib/bbz153 · DOI
- Xia, 2018, Predicting tumor cell line response to drug pairs with deep learning, BMC Bioinformatics, 19, 71
- Zagidullin, 2019, DrugComb: an integrative cancer drug combination data portal, Nucleic Acids Res, 47, W43, 10.1093/nar/gkz337 · DOI · Paper page
- Huang, 2014, DrugComboRanker: drug combination discovery based on target network analysis, Bioinformatics, 30, i228, 10.1093/bioinformatics/btu278 · DOI · Paper page
- Jeon, 2018, In silico drug combination discovery for personalized cancer therapy, BMC Syst Biol, 12
- Ianevski, 2019, Prediction of drug combination effects with a minimal set of experiments, Nat Mach Intell, 1, 568, 10.1038/s42256-019-0122-4 · DOI · Paper page
- Zhao, 2011, Prediction of drug combinations by integrating molecular and pharmacological data, PLoS Comput Biol, 7, 10.1371/journal.pcbi.1002323 · DOI · Paper page
- Li, 2015, Large-scale exploration and analysis of drug combinations, Bioinformatics, 31, 2007, 10.1093/bioinformatics/btv080 · DOI · Paper page
- Chen, 2016, NLLSS: predicting synergistic drug combinations based on semi-supervised learning, PLoS Comput Biol, 12, 10.1371/journal.pcbi.1004975 · DOI · Paper page
- Li, 2017, Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles, Artif Intell Med, 83, 35, 10.1016/j.artmed.2017.05.008 · DOI
- Held, 2013, Genotype-selective combination therapies for melanoma identified by high-throughput drug screening, Cancer Discov, 3, 52, 10.1158/2159-8290.CD-12-0408 · DOI · Paper page
- Liu, 2019, Predicting effective drug combinations using gradient tree boosting based on features extracted from drug-protein heterogeneous network, BMC Bioinformatics, 20, 1, 10.1186/s12859-019-3288-1 · DOI · Paper page
- Karimi, 2020, Network-principled deep generative models for designing drug combinations as graph sets, Bioinformatics, 36, i445, 10.1093/bioinformatics/btaa317 · DOI
- Sun, 2020, DTF: Deep tensor factorization for predicting anticancer drug synergy, Bioinformatics, 36, 4483, 10.1093/bioinformatics/btaa287 · DOI
- Kuhn, 2010, STITCH 2: an interaction network database for small molecules and proteins, Nucleic Acids Res, 38, D552, 10.1093/nar/gkp937 · DOI · Paper page
- Chen, 2002, Therapeutic target database, Nucleic Acids Res, 30, 412, 10.1093/nar/30.1.412 · DOI · Paper page
- Hamosh, 2005, Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders, Nucleic Acids Res, 33, D514
- Kanehisa, 2007, KEGG for linking genomes to life and the environment, Nucleic Acids Res, 36, D480, 10.1093/nar/gkm882 · DOI · Paper page
- Liu, 2007, BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities, Nucleic Acids Res, 35, D198, 10.1093/nar/gkl999 · DOI · Paper page
- Roth, 2000, The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?, Neuroscientist, 6, 252, 10.1177/107385840000600408 · DOI · Paper page
- Zhu, 2010, Update of TTD: therapeutic target database, Nucleic Acids Res, 38, D787, 10.1093/nar/gkp1014 · DOI · Paper page
- Forcina, 2017, Systematic quantification of population cell death kinetics in mammalian cells, Cell Systems, 4, 600, 10.1016/j.cels.2017.05.002 · DOI · Paper page
- Licciardello, 2017, A combinatorial screen of the cloud uncovers a synergy targeting the androgen receptor, Nat Chem Biol, 13, 771, 10.1038/nchembio.2382 · DOI
- Griner, 2014, High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells, Proc Natl Acad Sci, 111, 2349, 10.1073/pnas.1311846111 · DOI · Paper page
- Sun, 2016, Drug combination therapy increases successful drug repositioning, Drug Discov Today, 21, 1189, 10.1016/j.drudis.2016.05.015 · DOI · Paper page
- Liu, 2020, DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy, Nucleic Acids Res, 48, D871
Cited by
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Güvenç Paltun, B., Kaski, S., & Mamitsuka, H.
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-08-06
- Volume
- 22
- Issue
- 6
- ISSN
- 1467-5463
- 1477-4054
- Cited by
- 87
- References
- 20
- Language
- en
- Funders
- JST ACCEL (JPMJAC1503)
- MEXT Kakenhi (16H02868, 19H04169)
- Academy of Finland (315896)
- Finnish Center for Artificial Intelligence FCAI (320181)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Machine learning approaches for drug combination therapies. https://app.cochat.ai/papers/10.1093/bib/bbab293
- The paper
- Güvenç Paltun, B., Kaski, S., & Mamitsuka, H. (2021). Machine learning approaches for drug combination therapies. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbab293
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.